Cargando…
Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma
Therapeutic options for locally advanced pancreatic cancer (LAPC) include concurrent chemoradiation, induction chemotherapy followed by chemoradiation or systemic therapy alone. The original Gastro-Intestinal Study Group and Eastern Cooperative Oncology Group studies defined fluorouracil (5-FU) with...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114599/ https://www.ncbi.nlm.nih.gov/pubmed/25120712 http://dx.doi.org/10.3892/ol.2014.2238 |
_version_ | 1782328458444013568 |
---|---|
author | SAIF, MUHAMMAD WASIF LEDBETTER, LESLIE KALEY, KRISTIN GARCON, MARIE CARMEL RODRIGUEZ, TERESA SYRIGOS, KOSTAS N. |
author_facet | SAIF, MUHAMMAD WASIF LEDBETTER, LESLIE KALEY, KRISTIN GARCON, MARIE CARMEL RODRIGUEZ, TERESA SYRIGOS, KOSTAS N. |
author_sort | SAIF, MUHAMMAD WASIF |
collection | PubMed |
description | Therapeutic options for locally advanced pancreatic cancer (LAPC) include concurrent chemoradiation, induction chemotherapy followed by chemoradiation or systemic therapy alone. The original Gastro-Intestinal Study Group and Eastern Cooperative Oncology Group studies defined fluorouracil (5-FU) with concurrent radiation therapy followed by maintenance 5-FU until progression, as the standard therapy for this subset of patients. Although this combined therapy has been demonstrated to increase local control and median survival from 8 to 12 months, almost all patients succumb to the disease secondary to either local or distant recurrence. Our earlier studies provided a strong rationale for the use of capecitabine in combination with concurrent radiation followed by maintenance capecitabine therapy. To report our clinical experience, we retrospectively evaluated our patients who were treated with maintenance capecitabine. We reviewed the medical records of patients with LAPC who received treatment with capecitabine and radiation, followed by a 4-week rest, then capecitabine alone 1,000 mg twice daily (ECOG performance status 2 or age >70 years) or 1,500 mg twice daily for 14 days every 3 weeks until progressive disease. We treated 43 patients between September 2004 and September 2012. The population consisted of 16 females and 25 males, with a median age of 64 years (range, 38–80 years). Patients received maintenance capecitabine for median duration of 9 months (range, 3–18 months). The median overall survival (OS) for these patients was 17 months, with two patients still living and receiving therapy. The 6-month survival rate was 91% (39/43), 1-year survival rate was 72% (31/43) and 2-year OS rate was 26% (11/43). Grade 3 or 4 toxicity was observed rarely: Hand-foot syndrome (HFS) in two patients, diarrhea in one patient and peripheral neuropathy in one patient, and there was no mortality directly related to treatment. Capecitabine maintenance therapy following chemoradiation in LAPC offers an effective, tolerable and convenient alternative to 5-FU. To the best of our knowledge, this is the largest study of its kind which has determined the safety and efficacy of capecitabine maintenance therapy for patients with LAPC. |
format | Online Article Text |
id | pubmed-4114599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-41145992014-08-12 Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma SAIF, MUHAMMAD WASIF LEDBETTER, LESLIE KALEY, KRISTIN GARCON, MARIE CARMEL RODRIGUEZ, TERESA SYRIGOS, KOSTAS N. Oncol Lett Articles Therapeutic options for locally advanced pancreatic cancer (LAPC) include concurrent chemoradiation, induction chemotherapy followed by chemoradiation or systemic therapy alone. The original Gastro-Intestinal Study Group and Eastern Cooperative Oncology Group studies defined fluorouracil (5-FU) with concurrent radiation therapy followed by maintenance 5-FU until progression, as the standard therapy for this subset of patients. Although this combined therapy has been demonstrated to increase local control and median survival from 8 to 12 months, almost all patients succumb to the disease secondary to either local or distant recurrence. Our earlier studies provided a strong rationale for the use of capecitabine in combination with concurrent radiation followed by maintenance capecitabine therapy. To report our clinical experience, we retrospectively evaluated our patients who were treated with maintenance capecitabine. We reviewed the medical records of patients with LAPC who received treatment with capecitabine and radiation, followed by a 4-week rest, then capecitabine alone 1,000 mg twice daily (ECOG performance status 2 or age >70 years) or 1,500 mg twice daily for 14 days every 3 weeks until progressive disease. We treated 43 patients between September 2004 and September 2012. The population consisted of 16 females and 25 males, with a median age of 64 years (range, 38–80 years). Patients received maintenance capecitabine for median duration of 9 months (range, 3–18 months). The median overall survival (OS) for these patients was 17 months, with two patients still living and receiving therapy. The 6-month survival rate was 91% (39/43), 1-year survival rate was 72% (31/43) and 2-year OS rate was 26% (11/43). Grade 3 or 4 toxicity was observed rarely: Hand-foot syndrome (HFS) in two patients, diarrhea in one patient and peripheral neuropathy in one patient, and there was no mortality directly related to treatment. Capecitabine maintenance therapy following chemoradiation in LAPC offers an effective, tolerable and convenient alternative to 5-FU. To the best of our knowledge, this is the largest study of its kind which has determined the safety and efficacy of capecitabine maintenance therapy for patients with LAPC. D.A. Spandidos 2014-09 2014-06-11 /pmc/articles/PMC4114599/ /pubmed/25120712 http://dx.doi.org/10.3892/ol.2014.2238 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles SAIF, MUHAMMAD WASIF LEDBETTER, LESLIE KALEY, KRISTIN GARCON, MARIE CARMEL RODRIGUEZ, TERESA SYRIGOS, KOSTAS N. Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
title | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
title_full | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
title_fullStr | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
title_full_unstemmed | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
title_short | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
title_sort | maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114599/ https://www.ncbi.nlm.nih.gov/pubmed/25120712 http://dx.doi.org/10.3892/ol.2014.2238 |
work_keys_str_mv | AT saifmuhammadwasif maintenancetherapywithcapecitabineinpatientswithlocallyadvancedunresectablepancreaticadenocarcinoma AT ledbetterleslie maintenancetherapywithcapecitabineinpatientswithlocallyadvancedunresectablepancreaticadenocarcinoma AT kaleykristin maintenancetherapywithcapecitabineinpatientswithlocallyadvancedunresectablepancreaticadenocarcinoma AT garconmariecarmel maintenancetherapywithcapecitabineinpatientswithlocallyadvancedunresectablepancreaticadenocarcinoma AT rodriguezteresa maintenancetherapywithcapecitabineinpatientswithlocallyadvancedunresectablepancreaticadenocarcinoma AT syrigoskostasn maintenancetherapywithcapecitabineinpatientswithlocallyadvancedunresectablepancreaticadenocarcinoma |